Immunostimulating therapy and prevention of acute respiratory viral infections in children

Abstract

Acute respiratory infections (ARIs) have been holding leading positions in terms of prevalence rates in all age groups for much longer than one year, accounting for more than 70%. World Health Organization experts note that ARI is the most common group of diseases in the human population. Back in 1995, D.J. Rowlands stated in his publication that the average person has ARI for a total of about two years during his life. The published report “On the state of the sanitary and epidemic well-being of the population in the Russian Federation, 2017” showed that the acute respiratory viral infection (ARVI) and influenza rate has increased by 9.3% over the past 6 years, more than 20% of the population have ARVI annually and children of younger age groups account for 70–80% among them. The annual economic damage from the burden of influenza and SARS is estimated at more than 500 billion roubles. The use of drugs that can prevent the spread of ARI, prevent attachment of secondary bacterial infections, reduce the need for prescribing systemic antibacterial drugs will allow to reduce the antibiotic resistance in microbes. However, the existing medicinal products are mainly represented by vaccines and antiviral drugs against influenza in almost complete absence of drugs against other ARI pathogens. In 2013, the World Health Organization launched the BRaVE initiative to expand treatment options for ARVI with the development of effective antivirals against the most significant pathogens and/or safe and effective biological response modifiers.The article is devoted to the challenge of treatment and prevention of ARI in children, the therapeutic potential of a plant preparation containing aloe extract. The data presented in the clinical results review of the use of this drug prove the feasibility and safety of its introduction in the ARI treatment and prevention regimens in children.